Carl Zeiss adds glaucoma data to StratusOCT:
This article was originally published in Clinica
Carl Zeiss Meditec has launched a new version of its retinal imaging instrument StratusOCT in Europe and Asia with an enhancement that can help improve glaucoma diagnosis. The latest device incorporates retinal fibre layer (RNFL) normative data, which provides clinicians with the normal ranges of retinal layer thickness, against which they can judge the measurements from their patients. This new version is currently awaiting FDA approval in the US. StratusOCT, an optical coherence tomographer, is the first instrument to provide cross-sectional imaging of the retina using ordinary light instead of X-rays, according to the Dublin, California firm. Glaucoma affects three million people in the US and is the leading cause of preventable blindness.
You may also be interested in...
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
The Israeli biotech which is listed on the NASDAQ is in for a busy 2021 with strong marketing pushes for Movantik, Aemcolo and Talicia and completing a pivotal trial for COVID-19 hopeful opaganib.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.